greeksoup/ stock research
Stock research / United States / GMAB / Year to 31 December 2025

Genmab A/S (GMAB) annual results, year to 31 December 2025: revenue USD 3,720 million, from the 20-F

Genmab A/S files a 20-F with the SEC once a year, in US dollars. In the year to 31 December 2025 it reported revenue of USD 3,720 million, up 19.2% on the year before. Its profit was USD 963 million, down 15.0%, and diluted earnings per share USD 15.37.

Revenue
USD 3,720 million
+19.2% on the year
FY2023FY2025
Operating margin
28.6%
31.1% a year earlier
FY2023FY2025
Net income
USD 963 million
-15.0% on the year
FY2023FY2025
Diluted EPS
USD 15.37
-12.3% on the year
FY2023FY2025

this yearthe year beforeIn US dollars as filed. Hover a bar for its figure.

Income statement (profit and loss)

Year toDec 2024Dec 2025
Revenue3,1213,720
Cost of sales143238
Research and development1,4141,606
Selling, general and administrative549626
Operating profit9721,065
Finance costs291269
Profit before tax1,3261,204
Income tax193241
Profit for the year1,133963
Profit attributable to shareholders1,133963
Filing20-F20-F
USD million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated.
Year toDec 2024Dec 2025
Diluted EPS17.5315.37
Basic EPS17.6615.50
Filing20-F20-F

USD per ordinary share, as filed.

Cash flow

Year toDec 2024Dec 2025
Cash from operations1,1261,186
Purchase of property, plant and equipment27.037.0
Free cash flow1,0991,149
Cash from investing-1,447-5,643
Cash from financing-5664,789
Filing20-F20-F

USD million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.

Balance sheet

Year toDec 2024Dec 2025
Funded by
Equity attributable to shareholders5,1375,847
Borrowings, as filed0.05,274
Lease liabilities144152
Other liabilities1,1331,600
Total equity and liabilities6,41412,873
Owned
Property, plant and equipment137153
Goodwill355355
Other intangible assets1,7289,123
Cash and cash equivalents1,3801,715
Trade and other receivables9231,112
Inventories9.018.0
Other assets1,882397
Total assets6,41412,873
Filing20-F20-F

USD million, at each fiscal year end.

Ratios on the filed lines

Year toDec 2024Dec 2025
Operating margin31.1%28.6%
Net margin36.3%25.9%
Free cash flow margin35.2%30.9%
Return on year-end equity22.1%16.5%
Effective tax rate14.6%20.0%
Filing20-F20-F

Arithmetic on the filed lines of the same year.

20-F for the year to 31 December 2025, filed 17 February 2026: the filing. The figures are in US dollars as filed.